

# AMGEN INC.

ISIN: US0311621009

WKN: 031162100

Asset Class: Stock

## Company

2024/05/20 15:35:54

Price

**313.40**

USD

Difference



0.30%(0.93)



## Contact Details

AMGEN INC.

Tel: +1-805-447-1000

--

Fax: +1-805-447-1010

One Amgen Center Drive

Web: <http://www.amgen.com>

91320-1799 Thousand Oaks

E-mail: -

## Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures              | 2023           |                        | 2022           |                        | 2021           |                        |
|--------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| Current assets                 | 30,332,000,000 |                        | 22,186,000,000 |                        | 19,385,000,000 |                        |
| Common stock capital           |                | 33,070,000,000         |                | 32,514,000,000         |                | 32,096,000,000         |
| Fixed assets                   | 66,822,000,000 |                        | 42,935,000,000 |                        | 41,780,000,000 |                        |
| Equity capital of a company    |                | 6,232,000,000          |                | 3,661,000,000          |                | 6,700,000,000          |
| Cash and cash equivalents      | 10,944,000,000 |                        | 7,629,000,000  |                        | 7,989,000,000  |                        |
| Accrued liabilities            |                | 4,680,000,000          |                | 5,757,000,000          |                | 6,594,000,000          |
| Other assets                   |                | -                      |                | -                      |                | -                      |
| Current liabilities            |                | 18,392,000,000         |                | 15,687,000,000         |                | 12,184,000,000         |
| Prepayments and accrued income |                | -                      |                | -                      |                | -                      |
| Non-current liabilities        |                | 72,530,000,000         |                | 45,773,000,000         |                | 42,281,000,000         |
| Different income               |                | -                      |                | -                      |                | -                      |
| Other liabilities              |                | 1,635,000,000          |                | 2,123,000,000          |                | 1,940,000,000          |
| Total assets                   | 97,154,000,000 | 97,154,000,000         | 65,121,000,000 | 65,121,000,000         | 61,165,000,000 | 61,165,000,000         |

## Balance notes

|                     | 2023      | 2022      | 2021    |
|---------------------|-----------|-----------|---------|
| Accounting standard | US-GAAP   | US-GAAP   | US-GAAP |
| Employees           | 26,700    | 25,200    | 24,200  |
| Equity ratio        | 6.41%     | 5.62%     | 10.95%  |
| Debt-equity ratio   | 1,458.95% | 1,678.78% | 812.91% |

## Others

|                  | 2023   | 2022   | 2021   |
|------------------|--------|--------|--------|
| Tax Expense Rate | 14.49% | 10.81% | 12.06% |

# AMGEN INC.

ISIN: US0311621009

WKN: 031162100

Asset Class: Stock

## Income statement

|   | 2023           | 2022           | 2021           |
|---|----------------|----------------|----------------|
| Turnover  | 28,010,000,000 | 26,092,000,000 | 25,987,000,000 |
| Net income  | 6,717,000,000  | 6,552,000,000  | 5,893,000,000  |
| EBIT  | 9,953,803,400  | 8,127,206,400  | 7,349,637,400  |
| Operating income before taxes                                 | 7,855,000,000  | 7,346,000,000  | 6,701,000,000  |
| Cash Flow   | 8,471,000,000  | 9,721,000,000  | 9,261,000,000  |
| Net interest income   | -2,962,000,000 | -1,486,000,000 | -1,286,000,000 |
| Research and development expenses                             | 4,755,000,000  | 4,434,000,000  | 4,819,000,000  |
| Income taxes  | 1,138,000,000  | 794,000,000    | 808,000,000    |
| Result from investments in subsidiaries, associates and other | -              | -              | 0              |
| Revenues per employee   | 965,348        | 952,772        | 988,150        |

## Board of Directors

## Members of Management Board

|                   |                               |
|-------------------|-------------------------------|
| Brian Druker      | Member of Board of Directors  |
| Michael Drake     | Member of Board of Directors  |
| Omar Ishrak       | Member of Board of Directors  |
| Robert Williams   | Member of Board of Directors  |
| Ronald Sugar      | Member of Board of Directors  |
| Tyler Jacks       | Member of Board of Directors  |
| Wanda Austin      | Member of Board of Directors  |
| Amy Miles         | Member of Board of Directors  |
| Charles Holley    | Member of Board of Directors  |
| Ellen Kullman     | Member of Board of Directors  |
| Greg Garland      | Member of Board of Directors  |
| Robert Eckert     | Member of Board of Directors  |
| Robert A. Bradway | Chairman of Managing Board    |
| David M. Reese    | Member of Executive Committee |
| Jackie Elbonne    | Member of Executive Committee |
| James Bradner     | Member of Executive Committee |
| Jonathan Graham   | Member of Executive Committee |
| Mike Zahigan      | Member of Executive Committee |
| Murdo Gordon      | Member of Executive Committee |
| Paul Burton       | Member of Executive Committee |
| Peter Griffith    | Member of Executive Committee |